Skip to main content

$0.043 0.002 (4.88%)

High

$0.05

Low

$0.04

Trades

61

Turnover

$61,445

Volume

1,415,719
30 June 2023 at 4:10pm
Register to track NOX and receive email alerts.

First Patient Treated in CEP-2 Sarcoma Trial

StockBot

416,823 posts

NOX released this announcement to the ASX on 28 February 2022, 8:43. The announcement is marked as price sensitive, and is 2 page(s) in length and 200.85kb in size.

You can view all announcements from NOX and see how they appear on a price chart on the announcements page.

At the date of this announcement, NOX was 0.391% short sold according to ASIC data. It was ranked the 338th most shorted stock on the ASX. It remains ranked 566th as of the latest reported data (05 November 2025).

Other Recent Announcements from NOX
Change of Director's Interest Notice - FB 29 June 2023, 12:08
Change of Director's Interest Notice - FB 19 June 2023, 19:08
Change of Director's Interest Notice - BP 19 June 2023, 19:08
First Patient Treated in CEP-2 Sarcoma Trial 28 February 2022, 8:43
Appendix 4D and Half Year 2022 Financial Report 21 February 2022, 16:08
Initial Director's Interest Notice - GM 1 February 2022, 8:25
December 2021 Quarterly Activities Report and Appendix 4C 27 January 2022, 8:52
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track NOX and receive email alerts.